Bad Blood
Alfred A. Knopf (Verlag)
978-1-5247-1148-1 (ISBN)
- Titel erscheint in neuer Auflage
- Artikel merken
The full inside story of the breathtaking rise and shocking collapse of Theranos, the one-time multibillion-dollar biotech startup founded by Elizabeth Holmes-now the subject of the HBO documentary The Inventor-by the prize-winning journalist who first broke the story and pursued it to the end.
"The story is even crazier than I expected, and I found myself unable to put it down once I started. This book has everything: elaborate scams, corporate intrigue, magazine cover stories, ruined family relationships, and the demise of a company once valued at nearly $10 billion." -Bill Gates
In 2014, Theranos founder and CEO Elizabeth Holmes was widely seen as the female Steve Jobs: a brilliant Stanford dropout whose startup "unicorn" promised to revolutionize the medical industry with a machine that would make blood testing significantly faster and easier. Backed by investors such as Larry Ellison and Tim Draper, Theranos sold shares in a fundraising round that valued the company at more than $9 billion, putting Holmes's worth at an estimated $4.7 billion. There was just one problem: The technology didn't work.
A riveting story of the biggest corporate fraud since Enron, a tale of ambition and hubris set amid the bold promises of Silicon Valley.
JOHN CARREYROU is a two-time Pulitzer Prize-winning investigative reporter at The Wall Street Journal. For his extensive coverage of Theranos, Carreyrou was awarded the George Polk Award for Financial Reporting, the Gerald Loeb Award for Distinguished Business and Financial Journalism in the category of beat reporting, and the Barlett & Steele Silver Award for Investigative Business Journalism. Carreyrou lives in Brooklyn with his wife and three children.
Prologue November 17, 2006 Tim Kemp had good news for his team. The former IBM executive was in charge of bioinformatics at Theranos, a startup with a cutting-edge blood-testing system. The company had just completed its first big live demonstration for a pharmaceutical company. Elizabeth Holmes, Theranos's twenty-two-year-old founder, had flown to Switzerland and shown off the system's capabilities to executives at Novartis, the European drug giant. "Elizabeth called me this morning," Kemp wrote in an email to his fifteen-person team. "She expressed her thanks and said that, 'it was perfect!' She specifically asked me to thank you and let you all know her appreciation. She additionally mentioned that Novartis was so impressed that they have asked for a proposal and have expressed interest in a financial arrangement for a project. We did what we came to do!" This was a pivotal moment for Theranos. The three-year-old startup had progressed from an ambitious idea Holmes had dreamed up in her Stanford dorm room to an actual product a huge multinational corporation was interested in using. Word of the demo's success made its way upstairs to the second floor, where senior executives' offices were located. One of those executives was Henry Mosley, Theranos's chief financial officer. Mosley had joined Theranos eight months earlier, in March 2006. A rumpled dresser with piercing green eyes and a laid-back personality, he was a veteran of Silicon Valley's technology scene. After growing up in the Washington, D.C. area and getting his MBA at the University of Utah, he'd come out to California in the late 1970s and never left. His first job was at chipmaker Intel, one of the Valley's pioneers. He'd later gone on to run the finance departments of four different tech companies, taking two of them public. Theranos was far from his first rodeo. What had drawn Mosley to Theranos was the talent and experience gathered around Elizabeth. She might be young, but she was surrounded by an all-star cast. The chairman of her board was Donald L. Lucas, the venture capitalist who had groomed billionaire software entrepreneur Larry Ellison and helped him take Oracle Corporation public in the mid-1980s. Lucas and Ellison had both put some of their own money into Theranos. Another board member with a sterling reputation was Channing Robertson, the associate dean of Stanford's School of Engineering. Robertson was one of the stars of the Stanford faculty. His expert testimony about the addictive properties of cigarettes had forced the tobacco industry to enter into a landmark $6.5 billion settlement with the state of Minnesota in the late 1990s. Based on the few interactions Mosley had had with him, it was clear Robertson thought the world of Elizabeth. Theranos also had a strong management team. Kemp had spent thirty years at IBM. Diane Parks, Theranos's chief commercial officer, had twenty-five years of experience at pharmaceutical and biotechnology companies. John Howard, the senior vice president for products, had overseen Panasonic's chip-making subsidiary. It wasn't often that you found executives of that caliber at a small startup. It wasn't just the board and the executive team that had sold Mosley on Theranos, though. The market it was going after was huge. Pharmaceutical companies spent tens of billions of dollars on clinical trials to test new drugs each year. If Theranos could make itself indispensable to them and capture a fraction of that spending, it could make a killing. Elizabeth had asked him to put together some financial projections she could show investors. The first set of numbers he'd come up with hadn't been to her liking, so he'd revised them upward. He was a little uncomfortable with the revised numbers, but he figured they were in the realm of the plausible if the company executed perfectly. Besides, the venture capitalists startups cour
| Erscheinungsdatum | 22.05.2018 |
|---|---|
| Verlagsort | New York |
| Sprache | englisch |
| Maße | 155 x 234 mm |
| Gewicht | 544 g |
| Themenwelt | Literatur ► Biografien / Erfahrungsberichte |
| Wirtschaft ► Betriebswirtschaft / Management ► Finanzierung | |
| Wirtschaft ► Betriebswirtschaft / Management ► Unternehmensführung / Management | |
| Schlagworte | best books 2018 • best business books • best sellers list new york times 2019 • best sellers on amazon • biomedical engineering • book best sellers • books best sellers • business • Business book • business books • Elizabeth Holmes • finance books • great on kindle • his and hers gifts • Nonfiction • Non Fiction • non-fiction best sellers • non fiction books • nonfiction books • non fiction books best sellers • Science • Silicon Valley • Start up • Startup • technology books • the inventor • Theranos • True Crime • true crime books • Venture Capital |
| ISBN-10 | 1-5247-1148-9 / 1524711489 |
| ISBN-13 | 978-1-5247-1148-1 / 9781524711481 |
| Zustand | Neuware |
| Haben Sie eine Frage zum Produkt? |
aus dem Bereich
